280 related articles for article (PubMed ID: 28356890)
1. Evaluation and Optimization of
Gusman DH; Shoemake C
Yale J Biol Med; 2017 Mar; 90(1):15-23. PubMed ID: 28356890
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
[TBL] [Abstract][Full Text] [Related]
3. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
[TBL] [Abstract][Full Text] [Related]
4. The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases.
Mao-Draayer Y; Sarazin J; Fox D; Schiopu E
Clin Immunol; 2017 Feb; 175():10-15. PubMed ID: 27890706
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
Spampinato SF; Obermeier B; Cotleur A; Love A; Takeshita Y; Sano Y; Kanda T; Ransohoff RM
PLoS One; 2015; 10(7):e0133392. PubMed ID: 26197437
[TBL] [Abstract][Full Text] [Related]
6. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
Pérez-Jeldres T; Alvarez-Lobos M; Rivera-Nieves J
Drugs; 2021 Jun; 81(9):985-1002. PubMed ID: 33983615
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine-1-phosphate receptor modulators in stroke treatment.
Zhang W; Li Y; Li F; Ling L
J Neurochem; 2022 Sep; 162(5):390-403. PubMed ID: 35943290
[TBL] [Abstract][Full Text] [Related]
8. Lessons from S1P receptor targeting in multiple sclerosis.
Colombo E; Farina C
Pharmacol Ther; 2022 Feb; 230():107971. PubMed ID: 34450231
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
10. Second generation S1P pathway modulators: research strategies and clinical developments.
Bigaud M; Guerini D; Billich A; Bassilana F; Brinkmann V
Biochim Biophys Acta; 2014 May; 1841(5):745-58. PubMed ID: 24239768
[TBL] [Abstract][Full Text] [Related]
11. The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment.
Leo A; Citraro R; Marra R; Palma E; Paola EDD; Constanti A; De Sarro G; Russo E
CNS Neurol Disord Drug Targets; 2017; 16(3):311-325. PubMed ID: 27823573
[TBL] [Abstract][Full Text] [Related]
12. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Hla T; Brinkmann V
Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
[TBL] [Abstract][Full Text] [Related]
14. Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.
Comi G; Hartung HP; Bakshi R; Williams IM; Wiendl H
Drugs; 2017 Oct; 77(16):1755-1768. PubMed ID: 28905255
[TBL] [Abstract][Full Text] [Related]
15. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Groves A; Kihara Y; Chun J
J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
[TBL] [Abstract][Full Text] [Related]
16. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
Chun J; Brinkmann V
Discov Med; 2011 Sep; 12(64):213-28. PubMed ID: 21955849
[TBL] [Abstract][Full Text] [Related]
17. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Baumruker T; Billich A; Brinkmann V
Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors.
Delgado A; Martínez-Cartro M
Curr Med Chem; 2016; 23(3):242-64. PubMed ID: 26639095
[TBL] [Abstract][Full Text] [Related]
19. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.
Soliven B; Miron V; Chun J
Neurology; 2011 Feb; 76(8 Suppl 3):S9-14. PubMed ID: 21339490
[TBL] [Abstract][Full Text] [Related]
20. The organization of the sphingosine 1-phosphate signaling system.
Rosen H; Germana Sanna M; Gonzalez-Cabrera PJ; Roberts E
Curr Top Microbiol Immunol; 2014; 378():1-21. PubMed ID: 24728591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
